CVN398

CVN398 is a preclinical-stage therapeutic candidate being developed by Cerevance for the treatment of Parkinson's disease. The asset was identified using Cerevance's proprietary NETSseq (Nucleic Acid Enrichment in Specific Cell Types) platform, which analyzes gene expression in specific cell types from human brain tissue to identify novel, cell-type-specific targets. CVN398 is characterized as a potential disease-modifying therapy, intended to slow or halt the progression of Parkinson's disease rather than providing purely symptomatic relief. While the specific biological target and chemical structure have not been publicly disclosed, the program is part of a pipeline focused on CNS-active small molecules.

Other names

CVN398CVN-398CVN 398